09:00 AM EDT, 03/13/2024 (MT Newswires) -- BeiGene ( BGNE ) , the Max Foundation, and the charitable BeiGene Foundation said Wednesday the first doses of Brukinsa (zanubrutinib) have been provided to patients with chronic lymphocytic leukemia in Armenia and Nepal.

The organizations said they expect to deliver the medication in 29 low- and middle-income countries under their three-year partnership.

BeiGene ( BGNE ) provided Brukinsa free of charge as part of Max's Humanitarian Partnership for Access to Cancer Treatments, according to the companies.

Shares of BeiGene ( BGNE ) were up more than 10% in recent Wednesday premarket activity.

Price: 181.03, Change: +17.28, Percent Change: +10.55